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Amylin reduces plasma glucagon concentration in cats
Abstract
Pancreatic amylin plays an important role in the control of nutrient fluxes and is an established therapy
in human diabetes as it reduces post-prandial glucagon secretion and slows gastric emptying. Given the
similar pathophysiology of human type-2 and feline diabetes mellitus, we investigated whether amylin
reduces plasma glucagon levels in cats. Healthy cats were tested using an intravenous arginine
stimulation test (IVAST), a meal response test with the test meal comprising 50% of average daily food
intake, and an IV glucose tolerance test (IVGTT). Non-amyloidogenic rat amylin injected 5min before
the respective stimulus significantly reduced plasma glucagon levels under all test situations. In the
IVAST and IVGTT, cats treated with amylin also had lower plasma insulin concentrations. It was
concluded that amylin does reduce plasma glucagon levels in cats, a feature that has treatment potential
in diabetic animals as co-administration of amylin would reduce the insulin requirement to control
glycaemia.
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Abstract 19 
Pancreatic amylin plays an important role in the control of nutrient fluxes and is an 20 
established therapy in human diabetes as it reduces post-prandial glucagon secretion and slows 21 
gastric emptying. Given the similar pathophysiology of human type-2 and feline diabetes 22 
mellitus, we investigated if amylin reduces plasma glucagon levels in cats. Healthy cats were 23 
tested using an intravenous (IV) arginine stimulation test (IVAST), a meal response test (MRT) 24 
with the test meal comprising 50% of average daily food intake, and an IV glucose tolerance test 25 
(IVGTT). Non-amyloidogenic rat amylin injected 5 min before the respective stimulus 26 
significantly reduced plasma glucagon levels under all test situations. In the IVAST and IVGTT, 27 
cats treated with amylin also had lower plasma insulin concentrations. We conclude that amylin 28 
does reduce plasma glucagon levels in cats, a feature that has treatment potential in diabetic 29 
animals as co-administration of amylin would reduce the insulin requirement to control 30 
glycaemia. 31 
 32 
 33 
 34 
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Introduction 40 
Diabetes mellitus (DM) is a common endocrinopathy in cats. Its prevalence has risen 41 
over the last 30 years possibly reflecting the higher prevalence of obesity in this species. Cats are 42 
an interesting model of DM in that they spontaneously develop a form of the disease similar to 43 
human type-2 DM (T2DM) (Lutz and Rand, 1995; Cefalu, 2006; Henson and O’Brien, 2006). 44 
Diabetic cats are often middle aged and, similar to human T2DM, obesity with concurrent insulin 45 
resistance is a major risk factor, and impaired beta-cell function is present. The most striking 46 
histological similarity between human T2DM and the disease in cats is the amylin-derived islet 47 
amyloidosis that is found in > 80% of diabetic cats (Lutz and Rand, 1995). Primates and felines 48 
develop islet amyloidosis due to the amyloidogenic amino acid sequence of amylin while rodents 49 
do not spontaneously develop T2DM-like disease as their amylin is non-amyloidogenic 50 
(Westermark et al., 1990; Johnson et al., 1992). 51 
 52 
Amylin is a normal secretory product of pancreatic beta-cells, co-synthesised and co-53 
secreted with insulin in response to appropriate stimuli (Lutz and Rand, 1996; Young, 2005a) so 54 
that plasma insulin and amylin levels usually parallel each other. Early-stage or mild feline DM 55 
may be characterised by compensatory hyperinsulinaemia and absolute or relative 56 
hyperamylinaemia (O’Brien et al., 1991; Lutz and Rand, 1996). In such circumstances 57 
hyperamylinaemia may favour the deposition of amylin as pancreatic amyloid. Frequently 58 
however, clinical cases of feline DM are presented to veterinarians in more severe or late-stage 59 
disease by which time progressive beta-cell failure has resulted in overt hypoinsulinaemia and 60 
hypoamylinaemia (Johnson et al., 1989; Ludvik et al., 1991).  61 
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 62 
Amylin plays an important role in controlling nutrient metabolism through inhibiting pancreatic 63 
glucagon release and food intake (Lutz, 2005), and through slowing gastric emptying (Edelman and 64 
Weyer, 2002). In humans and in rodent animal models, lack of amylin in DM thus results in over-65 
secretion of glucagon, over-eating and accelerated gastric emptying. Amylin reduces the excessive post-66 
prandial hyperglucagonaemia observed in DM (Fineman et al., 2002) and normalises gastric emptying in 67 
human diabetics treated with pramlintide, a non-amyloidogenic amylin analogue (Thompson et al., 68 
1998; Weyer et al., 2001; Fineman et al., 2002; Ratner et al., 2002; Vella et al., 2002; Hollander et al., 69 
2003, 2004; Maggs et al., 2004). 70 
 71 
Hyperglucagonaemia is also a feature of diabetic cats (Tschuor et al., 2006), but it remains 72 
unknown if this is due to the lack of amylin. Given the similar pathophysiology of human T2DM and 73 
feline diabetes, and given that human diabetics are successfully treated with a combination of amylin 74 
and insulin, it seems pertinent to study the effect of amylin on glucagon secretion in cats. In this study 75 
we investigate the effect of amylin injection on plasma glucagon levels in healthy cats under three test 76 
conditions: an intravenous (IV) arginine stimulation test (IVAST); a meal response test (MRT); and an 77 
IV glucose tolerance test (IVGTT). Plasma glucagon levels increased in response to arginine injection 78 
and to feeding but were reduced following IV glucose administration. In our study we used rat amylin 79 
because of its non-amyloidogenic properties (Westermark et al., 1990; Johnson et al., 1992) and 80 
assessed if it reduced plasma glucagon concentrations under these test conditions in healthy cats. The 81 
doses of amylin used (5 or 10 µg/kg) were based on effective doses previously used in rats and humans 82 
(Young et al., 1996; Hollander et al., 2003; Lutz, 2005). 83 
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Materials and Methods 84 
The procedures were carried out on 12 male domestic short-hair cats (Harlan Sprague 85 
Dawley) that had been castrated between 5-10 months of age and were between 16-24 months 86 
old at the time of study. Their average bodyweight was 4.9 ± 0.4 kg. All experimental procedures 87 
were approved by The Cantonal Veterinary Office, Zurich, Switzerland (licence number 88 
213/2003 ZH).  89 
 90 
              During the study, cats were group-housed except when under test and were given a four 91 
week adaptation period prior to the start of the experiment. The animals were kept in artificial 92 
light with the light on from 07:00-19:00 and were offered commercial canned food (Purina 93 
Veterinary Diet, Diabetes Management, Nestlé Purina) twice daily. Food consumption was such 94 
that the cats maintained a stable bodyweight which was recorded weekly. Water was available ad 95 
libitum. 96 
Implantation of jugular catheter  97 
A 10 cm long jugular catheter (4 French polyurethane catheter, Global Veterinary 98 
Products) was inserted using the Seldinger technique (Seldinger, 1953) and sutured to the skin on 99 
the day prior to testing. Cats were sedated with ketamine (Ketaminol, Veterinaria) at a dose of 5-100 
7 mg/kg intramuscular (IM) and midazolam (Dormicum, Roche) at 0.2 mg/kg (IM), followed by 101 
IV propofol (Fresenius Kabi) at 6-7 mg/kg to anaesthetise.  102 
Pharmacokinetic of rat amylin in cats 103 
We determined the pharmacokinetics of rat amylin in four cats in a pilot experiment. Rat 104 
amylin (Amylin Pharmaceuticals Inc.) was used as, in contrast to cat amylin, it is non-105 
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amyloidogenic. The dose of amylin used (5 µg/kg dissolved in 0.1 mL/kg saline) was based on 106 
that effective in rats and humans (Young et al., 1996; Hollander et al., 2003; Lutz, 2005) and was 107 
administered subcutaneously (SC). Blood samples were taken into EDTA tubes 5, 10, 15, 20, 25 108 
and 30 min after injection and centrifuged immediately. Aprotinine (Trasylol, Bayer) was added 109 
to the EDTA-plasma mixture at 500 kIU/mL. Plasma samples were frozen at –80 °C until further 110 
analysis.  111 
Intravenous arginine stimulation test  112 
The IVAST was used to investigate the effect of amylin on arginine induced glucagon 113 
secretion.  Six cats per group were fasted overnight for 12 h before testing. After taking a 2 mL 114 
basal blood sample, amylin (5 or 10 µg/kg) or saline solution (control treatment, 0.1 mL/kg) 115 
were injected SC. Five min following amylin or saline administration (t = 0), L-arginine (0.2 116 
g/kg, L-arginine hydrochloride 21%, B. Braun Melsungen) was injected via the catheter. Blood 117 
samples were taken 2, 4, 7, 9, 15, 25 and 30 min after L-arginine injection. These sampling 118 
points were chosen based on previous studies (Tschuor et al., 2006). Volume replacement was 119 
achieved by injecting 0.9% saline solution. Blood was taken into fluoride blood tubes (to 120 
measure glucose concentrations), and into EDTA tubes (to measure insulin and glucagons 121 
concentrations) and was centrifuged immediately. EDTA-plasma was treated as described above.  122 
Meal response test  123 
               Six cats per group were fasted for 24 h before the MRT which was carried out at the 124 
onset of the light period. After taking a 2 mL basal blood sample, amylin (5 µg/kg) or saline 125 
solution (control treatment, 0.1 mL/kg) were injected SC and 5 min later, the test meal 126 
comprising 50% of the average daily food intake was offered. All food was consumed within 10 127 
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min and at this time (t = 0), a second blood sample was obtained. Further samples were taken 15 128 
and 30 min and 1, 2 and 5 h later, sampling time-points based on pilot studies. Volume 129 
replacement was achieved by injecting 0.9% saline solution and blood samples were treated as 130 
described above. 131 
Intravenous glucose tolerance test 132 
                   Six cats per group were fasted for 12h overnight before the IVGTT. After taking a 2 133 
mL basal blood sample, amylin (5 or 10 µg/kg) or saline solution (control treatment, 0.1 mL/kg) 134 
were injected SC and 5 min later (t = 0), D-glucose (0.5 g/kg, 50 % sterile dextrose; 1 mL/kg) 135 
was injected slowly over 30 s via the catheter. Blood samples were taken 3, 7, 10, 15, 30, 60, 120 136 
and 180 min after glucose injection, sampling time-points based on previous studies (Lutz and 137 
Rand, 1996). Volume replacement was achieved by injecting 0.9% saline solution and blood 138 
samples were treated as described above. 139 
Biochemical analysis 140 
        The blood glucose concentration was measured using an automated photometric test 141 
and the hexokinase method (Cobas Integra Analyser, Roche). Amylin was measured by an in-142 
house radioimmunoassay (RIA). In brief, antibodies directed against rat amylin (T-486-6; rabbit 143 
anti-rat-amylin antibodies; kindly provided by T. Pieber, Graz, Austria) were dissolved in 144 
phosphate buffer containing Na2HPO4 (50 mMol/L, pH 7.2), aprotinine (1%), EDTA (0.25%), 145 
Triton X 100 (0.2%), fish gelatine (0.1%) and sodium azide (0.02%) (all Sigma). Antibodies 146 
were used at a final dilution of 1:50,000 and rat amylin (Peninsula Laboratories) was used as a 147 
standard. Samples and standards were incubated for 72 h at 4 °C. Radiolabeled amylin (125I-148 
amylin, 9,000-10,000 cpm, Amersham) was added and samples were incubated for 96 h at 4 °C. 149 
Goat anti-rabbit antibodies (Sigma) and polyethylene glycol were added to separate bound from 150 
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unbound amylin. Radioactivity was counted by gamma-counter (GAMMAmatic 1, Kontron 151 
Analytical).  152 
  153 
   Insulin and glucagon were measured using commercial RIA kits: insulin using the 154 
Linco Porcine Insulin RIA Kit (# PI-12K, Millipore); and glucagon using the ICN Biomedicals 155 
kit (# 07152101, MP Biomedicals Europe), both of which were validated prior to use. For the 156 
insulin assay, inter- and intra-assay coefficients of variation were 7.0 % and 6.5% respectively 157 
and the sensitivity was approximately 0.3 µIU/mL (2 pMol/L). Observed-to-expected ratios for 158 
serial dilutions (12.5–100%) ranged from 103.2–106.4% (Zini et al., 2008). For the glucagon 159 
assay, inter- and intra-assay coefficients of variation were 8.2 % and 7.5% respectively and the 160 
sensitivity was approximately 50 pg/mL. 161 
Statistical analysis 162 
The area under the curve (AUC) was calculated above the baseline of each individual 163 
animal using GraphPad Prism software (GraphPad Inc.) and these values were used to compute 164 
the average AUC. All values are given as mean ± standard error of the mean (SEM). The 165 
experiments were performed using cross-over design with at least 4 weeks between trials. 166 
Statistical tests applied included paired Student’s t-tests or repeated measures ANOVA, as 167 
appropriate and P values < 0.05 were considered significant. 168 
 169 
 170 
 171 
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Results 172 
Pharmacokinetics of rat amylin in cats 173 
Since no data were available relating to the pharmacokinetics of exogenous amylin in 174 
cats, we performed a pilot experiment to investigate the time course of plasma amylin levels 175 
following the SC administration of a bolus of rat amylin. The rabbit anti-rat-amylin antibodies 176 
used do not cross-react with cat amylin (own unpublished obervation) and can therefore be used 177 
to differentiate between exogenous rat and endogenous cat amylin. Rat amylin was not detected 178 
at t = 0 min. The concentration of rat amylin peaked at the first sampling time-point, 5 min after 179 
administration and its estimated half-life was approximately 8.4 min. By 30 min after 180 
administration, rat amylin was largely cleared from the circulation (Fig. 1). 181 
Intravenous arginine stimulation test  182 
Arginine injection resulted in a slight increase in plasma glucose levels in all groups of 183 
approximately 1.5 mMol/L. By 30 min after injection, plasma glucose levels had returned to 184 
baseline values. Amylin had no effect on the plasma glucose concentration at any time-point 185 
(Fig. 2A). Plasma insulin increased approximately 6-fold following arginine administration 186 
(from 7.1 µIU/mL at t = 0 to 45.4 ± 10.2 µIU/mL at t = 7 min). Interestingly, the arginine-187 
induced increase in the plasma insulin concentration was lower in cats previously given amylin 188 
(Fig. 2B). Arginine administration also increased plasma glucagon levels and this increase was 189 
reduced following amylin administration (Fig. 2C). Amylin treatment reduced the total glucagon 190 
secretory response relative to that of control cats, as indicated by the AUC within the first 15 min 191 
of its administration (Fig. 2D). Both doses of amylin produced similar effects. 192 
  193 
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Meal response test  194 
         Ingestion of the meal did not result in post-prandial hyperglycaemia, irrespective of 195 
treatment so that the plasma glucose concentration was unaffected by amylin administration (Fig. 196 
3A). The post-prandial plasma insulin concentration increased approximately 3-fold relative to 197 
fasting levels peaking at 24.3 ± 5.5 µIU/mL immediately when the meal ended and had returned 198 
to baseline values within 5 h. The total insulin secretion, as indicated by the AUC, was not 199 
affected by amylin administration (data not shown). Plasma glucagon concentrations peaked 200 
approximately 1 h after the meal (570 ± 55 pg/mL relative to the baseline value of 265 ± 35 201 
pg/mL) and the total secretion of this hormone over the first hour after the meal, as indicated by 202 
the AUC, was significantly reduced by amylin administration (Fig. 3B). 203 
 204 
Intravenous glucose tolerance test  205 
The IV administration of glucose increased the plasma glucose concentration in control 206 
cats from a baseline of 4.5 ± 0.2 mMol/L to 29.7 ± 4.5 mMol/L in 3 min. Plasma glucose 207 
concentrations and the time course of glucose were unaffected by amylin administration. 208 
Interestingly, the total insulin output, as indicated by the AUC, was significantly lower in cats 209 
that had been given amylin (Fig. 4A). Glucose administration resulted in a time-dependent 210 
decrease in plasma glucagon concentrations which was more pronounced in amylin-treated cats 211 
relative to controls (Fig. 4B). Both doses of amylin produced similar effects. 212 
Discussion 213 
Amylin plays an important role in the control of nutrient metabolism in rodents and 214 
humans, decreasing the excessive post-prandial hyperglucagonaemia observed in DM and 215 
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slowing gastric emptying (Edelman and Weyer, 2002; Fineman et al., 2002; Lutz, 2005). 216 
Although aggressive insulin treatment can almost normalise mean blood glucose levels in 217 
diabetics, enhanced control of post-prandial hyperglycaemia is required for optimal glycaemic 218 
homeostasis (Ceriello et al., 2008). This can be achieved by a combination treatment of insulin 219 
and amylin, the latter controlling post-prandial glucagon release, an approach that is now used 220 
successfully to treat human DM (Thompson et al., 1998, Weyer et al., 2001, Fineman et al., 221 
2002; Ratner et al., 2002; Vella et al., 2002; Hollander et al., 2003, 2004; Maggs et al., 2004).  222 
 223 
The results of the present study indicate that similar mechanisms, at least with respect to 224 
the control of plasma glucagon, may operate in the cat. Our findings indicate that a single amylin 225 
injection lowers plasma glucagon levels under all three test conditions. Blood insulin 226 
concentrations were also lowered following amylin administration in the IVAST and IVGTT 227 
relative to controls. Intravenous arginine resulted in a slight increase in plasma glucose levels 228 
and, as expected, insulin and glucagon concentrations increased (Kitamura et al., 1999). 229 
Importantly, the increase in plasma glucagon was significantly reduced by amylin. This was 230 
paralleled by a reduction in overall insulin secretion relative to the controls.  231 
 232 
Amylin administration also reduced post-prandial glucagon secretion in the MRT. This 233 
test mimics normal circumstances indicating that amylin may have therapeutic potential in 234 
controlling post-prandial nutrient metabolism in diabetic cats. Interestingly, this feature is 235 
considered one of the most significant benefits of the combination insulin-amylin treatment in 236 
human diabetics (Young, 2005c). The IVGTT also confirmed amylin’s potency in controlling 237 
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plasma glucagon levels. Glucose injection resulted in an expected decrease in the plasma 238 
glucagon concentration which was enhanced by amylin administration, and was paralleled by 239 
reduced insulin secretion in amylin-treated cats. It is likely that the lower insulin response in the 240 
IVAST and IVGTT following amylin administration was secondary to amylin’s effect on 241 
glucagon secretion. Although amylin reduces insulin secretion, the low doses of amylin used in 242 
the current study are unlikely to have resulted in such an effect (Young, 2005b). However, this 243 
issue requires further study. The fact that insulin secretion during the MRT appeared unaffected 244 
by amylin administration may be attributable to the smaller increase in the insulin concentration 245 
in this test relative to the IVAST and IVGTT. The latter two tests would act as more intense 246 
stimulants of insulin release than food intake, so that the short-term influence of amylin on 247 
insulin levels in the MRT may not be as easily detected. Given that the pharmacokinetics of rat 248 
amylin in cats indicates its plasma half-life is similar to that in other species (Young et al., 1996; 249 
Young, 2005a), if amylin were to be used in the treatment of feline diabetes, it would require 250 
repeated injection as is the case in humans where two to three meal-contingent injections are 251 
recommended Young, 2005c). 252 
 253 
A limitation of our study was that, given the effects of amylin on plasma glucagon levels 254 
were small, they may not be of great clinical significance. The effects of amylin were not dose-255 
dependent at the two doses we tested and also it must be noted that the cats used in our study 256 
were young, healthy and of normal body weight. However, even in such animals, with fully 257 
functional endocrine systems, the effect of amylin on the plasma glucagon concentration was 258 
found and we suggest this response may be much more pronounced in diabetic cats. Although 259 
amylin secretion may be increased initially in diabetics, the later stages of the disease are 260 
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characterised by marked hypoamylinaemia (Lutz and Rand, 1996; Young, 2005a,c), so that any 261 
effect of exogenous amylin is likely to be much more pronounced in diabetic cats. 262 
 263 
Although the effects of amylin were relatively short-term and occurred at slightly 264 
different time-points in the three tests, we do not consider that this precludes the use of amylin as 265 
an adjunct treatment in diabetes. The current experiment was a ‘proof-of-concept’ study of the 266 
effect of amylin in the cat. The amylin analogue pramlintide, with similar pharmacodynamics to 267 
the amylin preparation used in our study (Young et al., 1996), has been used to successfully treat 268 
T2DM in humans (Fineman et al., 2002; Maggs et al., 2004) and longer acting amylin 269 
compounds are in development. Other limitations to the present study that must be borne in mind 270 
were the relatively small number of cats used and the fact that plasma glucagon concentrations 271 
and not direct secretion were measured. Given that amylin is unlikely to influence renal glucagon 272 
clearance, we suggest that plasma glucagon concentrations reliably reflect pancreatic alpha cell 273 
secretion. 274 
Conclusions 275 
This study provides the first evidence that amylin lowers plasma glucagon concentrations 276 
in the cat. Amylin may therefore have therapeutic potential in diabetic cats, as it has in humans 277 
given that hyperglucagonaemia is a feature of the disease in both species (Tschuor et al., 2006). 278 
The dose of amylin used in this study was comparable to that used in humans and we did not 279 
observe any adverse effects of the treatment. Given the similar pathophysiology of human T2DM 280 
and feline diabetes, and the success in treating human diabetics with a combination of amylin 281 
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and insulin, we propose that amylin may have potential use as an adjunct to insulin in the 282 
treatment of diabetic cats, reducing the insulin requirement to control glycaemia. 283 
 284 
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Figure Legends 384 
Fig. 1 385 
Graph illustrating the time course of the plasma amylin concentration (pMol/L) following the SC 386 
injection of rat amylin (5 µg/kg) at t = 0 min (n = 4). The assay only detected exogenous (rat) 387 
and not endogenous (cat) amylin.  388 
 389 
‘y’ axis label – Amylin (pMol/L),   390 
‘x’ axis label – Time after amylin administration (min) 391 
 392 
Fig. 2 393 
Graphs illustrating the influence of the subcutaneous administration of amylin (at 5 or 10 µg/kg), 394 
or a saline control, on the plasma concentration of glucose (A), insulin (B) and glucagon (C and 395 
D) in an arginine stimulation test in six cats fasted for 12 h. Amylin or saline were administered 396 
5 min before arginine (0.2g/kg). The experiment was performed using a cross-over design. (A) 397 
Time course of plasma glucose concentration following the administration of arginine, (B) 398 
Amylin significantly reduced insulin secretion as assessed by the area under the curve (AUC) 399 
during the first 15 min following arginine administration, (C) Amylin significantly reduced 400 
plasma glucagon concentrations at 2, 4 and 30 min following arginine administration, (D) 401 
Amylin significantly reduced glucagon secretion as assessed by the AUC during the first 15 min 402 
following arginine administration. BL = baseline value just prior to administration of amylin or 403 
saline. * P < 0.05, **P < 0.01, significantly different from control. 404 
 405 
Fig 2A ‘y’ axis label – Glucose (mMol/L), ‘x’ axis label – Time after amylin administration 406 
(min) 407 
Fig 2B ‘y’ axis label – Insulin (μIU/mL X 15 min)  408 
Fig 2C ‘y’ axis label – Glucagon (pg/mL), ‘x’ axis label – Time after amylin administration 409 
(min) 410 
Fig 2D ‘y’ axis label – Glucagon (μIU/mL X 15 min) 411 
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Fig. 3 412 
Graphs illustrating the influence of the subcutaneous administration of amylin (5 µg/kg), or a 413 
saline control, on the plasma concentration of glucose (A) and glucagon (B) in a meal response 414 
test in six cats fasted for 24 h. Amylin or saline were administered 5 min before ingestion of the 415 
meal which lasted for approximately 10 min. The experiment was performed using a cross-over 416 
design. (A) The post-prandial glucose concentration did not increase above baseline values, (B) 417 
Amylin significantly reduced glucagon secretion as assessed by the AUC 1 h after the end of the 418 
meal. BL = baseline value just prior to the administration of amylin or saline. * P < 0.05, 419 
significantly different from control. 420 
 421 
Fig 3A ‘y’ axis label – Glucose (mMol/L), ‘x’ axis label – Time after end of meal (h) 422 
Fig 3B ‘y’ axis label – Glucagon (pg/mL X 1 h)  423 
 424 
Fig. 4 425 
Graphs illustrating the influence of the subcutaneous administration of amylin (5 or 10 µg/kg), or 426 
a saline control, on the plasma concentration of insulin and glucagon in an intravenous glucose 427 
tolerance test in six cats fasted for 12 h. Amylin or saline were administered 5 min prior to 428 
glucose administration (0.5g/kg). The experiment was performed using a cross-over design. (A) 429 
Insulin secretion in the 30 min following glucose administration was lower in amylin-treated 430 
cats, (B) Amylin significantly reduced plasma glucagon secretion 3, 7 and 10 min after 431 
administration. BL = baseline value just prior to the administration of amylin or saline. * P < 432 
0.05, **P < 0.01, significantly different from control. 433 
 434 
Fig 4A ‘y’ axis label – Insulin (μIU/mL X 30 min) 435 
Fig 4B ‘y’ axis label – Glucagon (pg/mL), ‘x’ axis label – Time after glucose administration 436 
(min). 437 
 438 
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